FSD Pharma Announces Closing of C$10.125 Million Private Placement to Institutional Investors
June 09 2020 - 11:30AM
Business Wire
FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE.CN) (FRA: 0K9A)
(the “Company”) announces the closing of a previously announced
private placement of 1,500,000 of the Company’s Class B Subordinate
Voting Shares (“Shares”) at a price of C$6.75 per Share and
warrants to purchase 1,500,000 Shares (cumulatively, the
”Securities”) of the Company to certain institutional investors for
gross proceeds, before deducting placement fees and other estimated
offering expenses payable by the Company, of approximately C$10.125
million. The warrants have a five-year term and an exercise price
of C$9.65 per share.
The Company has also granted the placement agents an option to
arrange for purchases of up to an additional C$10.125 million of
Securities on the terms above for a period of 30 days following the
initial closing. The net proceeds from this private placement are
expected to be used for working capital and other general corporate
purposes.
The securities sold in this private placement were issued
pursuant to an exemption from registration under the Securities Act
of 1933 (the “Securities Act”). The Securities have not been and
will not be registered under the Securities Act, or applicable
state securities laws, and accordingly may not be offered or sold
in the United States except pursuant to an effective registration
statement or an applicable exemption from the registration
requirements of the Securities Act and such applicable state
securities laws.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy nor shall there be any sale of
these securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction.
About FSD Pharma
FSD Pharma Inc. (Nasdaq: HUGE; CSE: HUGE.CN; FRA: 0K9A) is a
publicly traded holding company, since May 2018.
FSD BioSciences Inc., a wholly-owned subsidiary, is a specialty
biotech pharmaceutical R&D company focused on developing over
time a robust pipeline of FDA-approved synthetic compounds
targeting the endocannabinoid system of the human body to treat
certain diseases of the central nervous system and autoimmune
disorders of the skin, GI tract and the musculoskeletal system.
Through our acquisition of Prismic Pharmaceuticals in 2Q19, the
Company is also making an effort to help address the opioid crisis
by developing opioid-sparing prescription drugs utilizing the
ultramicronized formulation of palmitoylethanolamide (PEA).
The Company has a Phase 1 first-in-human safety and tolerability
trial for its lead candidate, FSD-201, currently underway in
Australia.
FSD's wholly-owned subsidiary, FV Pharma, is a licensed producer
under Canada's Cannabis Act and Regulations, having received its
cultivation license on October 13, 2017, and its full Sale for
Medical Purposes license on June 21, 2019 . The Company is licensed
to cultivate cannabis in approximately 25,000 square feet of its
facility in Cobourg, Ontario.
Forward-Looking Statements
Neither the Canadian Securities Exchange nor its regulation
services provider accept responsibility for the adequacy or
accuracy of this release.
Certain statements contained in this press release constitute
"forward-looking information" and "forward-looking statements"
within the meaning of applicable Canadian and U.S. securities laws
(collectively, "Forward-Looking Information"). Forward-Looking
Information includes, but is not limited to, information with
respect to FSD Pharma's strategy, plans or future financial or
operating performance, receipt of any U.S. Food and Drug
Administration ("FDA") approvals, the costs associated with such
planned trials, our ability to obtain required funding and the
terms and timing thereof, development of any FDA approved synthetic
compounds, the successful treatment of diseases by such compounds,
the ability to address the opioid crisis, the development of opioid
sparing prescription drugs utilizing the micronized formulations of
palmitoylethanolamide ("PEA"), and the objectives and timing of the
initiation of Phase 1 first-in-human safety and tolerability trials
for FSD 201 micro-PEA. The use of words such as "budget", "intend",
"anticipate", "believe", "expect", "plan", "forecast", "future",
"target", "project", "capacity", "could", "should", "focus",
"proposed", "scheduled", "outlook", "potential", "estimate" and
other similar words, and similar expressions and statements
relating to matters that are not historical facts, or statements
that certain events or conditions "may" or "will" occur, are
intended to identify Forward-Looking Information and are based on
FSD Pharma's current beliefs or assumptions as to the outcome and
timing of such future events. Such beliefs or assumptions
necessarily involve known and unknown risks and uncertainties that
could cause actual results to differ materially from those
expressed or implied in such Forward‐Looking Information. Certain
of these risks and uncertainties are described in the Company's
continuous disclosure filings available under the Company's SEDAR
profile at www.sedar.com. Forward‐Looking Information is not a
guarantee of performance. The Forward-Looking Information contained
in this press release is made as of the date hereof, and FSD Pharma
is not obligated to update or revise any Forward-Looking
Information, whether as a result of new information, future events
or otherwise, except as required by law. Because of the risks,
uncertainties and assumptions contained herein, investors should
not place undue reliance on Forward Looking-Information. The
foregoing statements expressly qualify any Forward-Looking
Information contained herein.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200609005603/en/
For further information: Sandy Huard, Head of
Communications, FSD Pharma, Inc. sandy@fsdpharma.com (647) 864-7969
Investor Relations IR@fsdpharma.com www.fsdpharma.com Or
LHA Investor Relations Sanjay M. Hurry shurry@lhai.com (212)
838-3777
FSD Pharma (NASDAQ:HUGE)
Historical Stock Chart
From Mar 2024 to Apr 2024
FSD Pharma (NASDAQ:HUGE)
Historical Stock Chart
From Apr 2023 to Apr 2024